tranexamic acid has been researched along with Adverse Drug Event in 10 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An open-label, extension clinical study was conducted to assess the safety of a novel, oral formulation of tranexamic acid (TA) in women with cyclic heavy menstrual bleeding." | 9.15 | Safety of tranexamic acid in women with heavy menstrual bleeding: an open-label extension study. ( Adomako, TL; Baker, J; Freeman, EW; Lukes, AS; Van Drie, D, 2011) |
| "An open-label, extension clinical study was conducted to assess the safety of a novel, oral formulation of tranexamic acid (TA) in women with cyclic heavy menstrual bleeding." | 5.15 | Safety of tranexamic acid in women with heavy menstrual bleeding: an open-label extension study. ( Adomako, TL; Baker, J; Freeman, EW; Lukes, AS; Van Drie, D, 2011) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M | 2 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Ding, D | 1 |
| Kelly, R | 1 |
| El Hanache, H | 1 |
| Verdaguer, M | 1 |
| Collin, L | 1 |
| Babin, M | 1 |
| Favrelière, S | 1 |
| Vidal Husser, S | 1 |
| Maissiat, MH | 1 |
| Hoppe, A | 1 |
| Morisset, M | 1 |
| Filipek, DR | 1 |
| Zhang, Y | 1 |
| Bai, Y | 1 |
| Zhou, Y | 1 |
| Yu, X | 1 |
| Zhou, H | 1 |
| Chen, G | 1 |
| Henry, D | 1 |
| Carless, P | 1 |
| Fergusson, D | 1 |
| Laupacis, A | 1 |
| Lukes, AS | 1 |
| Freeman, EW | 1 |
| Van Drie, D | 1 |
| Baker, J | 1 |
| Adomako, TL | 1 |
| Levy, JH | 1 |
| Karkouti, K | 1 |
| Beattie, WS | 1 |
| Dattilo, KM | 1 |
| McCluskey, SA | 1 |
| Ghannam, M | 1 |
| Hamdy, A | 1 |
| Wijeysundera, DN | 1 |
| Fedorko, L | 1 |
| Yau, TM | 1 |
| Lozano, M | 1 |
| Basora, M | 1 |
| Peidro, L | 1 |
| Merino, I | 1 |
| Segur, JM | 1 |
| Pereira, A | 1 |
| Salazar, F | 1 |
| Cid, J | 1 |
| Lozano, L | 1 |
| Mazzara, R | 1 |
| Macule, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Use of Tranexamic Acid to Reduce Perioperative Blood Loss During High Risk Spine Fusion Surgery[NCT01728636] | Phase 2 | 61 participants (Actual) | Interventional | 2013-01-15 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Total additional blood products (fresh frozen plasma, cryoprecipitate, and platelets) transfused in the perioperative period measured in units. (NCT01728636)
Timeframe: 24 hours after skin incision
| Intervention | Units (Mean) |
|---|---|
| Tranexamic Acid | 1 |
| Placebo | 2 |
Estimated Intraoperative blood loss in milliliters (mLs) (NCT01728636)
Timeframe: Incision to skin closure (approximately 10 hours)
| Intervention | Milliliters (Mean) |
|---|---|
| Tranexamic Acid | 1550 |
| Placebo | 1600 |
Number of participants who experienced arterial or venous thromboembolism, neurologic complications (including stroke, seizure,and delirium), infections, and pulmonary renal or cardiac adverse outcomes (demand ischemia, myocardial infarction or new arrhythmia) before another operative procedure or hospital discharge. (NCT01728636)
Timeframe: Time of surgery to date of discharge from hospital (average 7 days)
| Intervention | Participants (Count of Participants) |
|---|---|
| Tranexamic Acid | 9 |
| Placebo | 9 |
Total operating room time from incision to closure of incision in minutes. (NCT01728636)
Timeframe: Minutes
| Intervention | Minutes (Median) |
|---|---|
| Tranexamic Acid | 602 |
| Placebo | 576 |
Total red blood cells transfused in the intraoperative period in (mL). Total RBC equal packed red blood cells and cell saver infusion. (NCT01728636)
Timeframe: Intraoperative period (approximately 12 hours)
| Intervention | milliliters (Median) |
|---|---|
| Tranexamic Acid | 1140 |
| Placebo | 1460 |
Total milligrams of intravenous tranexamic acid administered during the surgical procedure. (NCT01728636)
Timeframe: Intraoperative period
| Intervention | milligrams (Median) |
|---|---|
| Tranexamic Acid | 1408 |
| Placebo | 0 |
2 reviews available for tranexamic acid and Adverse Drug Event
| Article | Year |
|---|---|
The safety and efficiency of intravenous administration of tranexamic acid in coronary artery bypass grafting (CABG): a meta-analysis of 28 randomized controlled trials.
Topics: Administration, Intravenous; Antifibrinolytic Agents; China; Coronary Artery Bypass; Drug-Related Si | 2019 |
The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis.
Topics: Adult; Aminocaproic Acid; Antifibrinolytic Agents; Aprotinin; Blood Loss, Surgical; Coronary Artery | 2009 |
2 trials available for tranexamic acid and Adverse Drug Event
| Article | Year |
|---|---|
Safety of tranexamic acid in women with heavy menstrual bleeding: an open-label extension study.
Topics: Adolescent; Adult; Antifibrinolytic Agents; Double-Blind Method; Drug-Related Side Effects and Adver | 2011 |
Effectiveness and safety of tranexamic acid administration during total knee arthroplasty.
Topics: Aged; Aged, 80 and over; Antifibrinolytic Agents; Arthroplasty, Replacement, Knee; Blood Loss, Surgi | 2008 |
6 other studies available for tranexamic acid and Adverse Drug Event
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Two Cases of Anaphylaxis to Tranexamic Acid Confirmed by Drug Provocation Test: What About Skin Tests?
Topics: Adolescent; Anaphylaxis; Bronchial Spasm; Drug Hypersensitivity; Drug-Related Side Effects and Adver | 2021 |
Tranexamic Acid in Total Hip Arthoplasty: Management of Complications and Use.
Topics: Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Drug Dosage Calculations; Drug-Relat | 2017 |
Aprotinin versus tranexamic acid: the controversy continues.
Topics: Adult; Antifibrinolytic Agents; Aprotinin; Blood Platelet Disorders; Blood Transfusion; Cardiac Surg | 2006 |
A propensity score case-control comparison of aprotinin and tranexamic acid in high-transfusion-risk cardiac surgery.
Topics: Adult; Antifibrinolytic Agents; Aprotinin; Blood Platelet Disorders; Blood Transfusion; Cardiac Surg | 2006 |